Supernus Pharmaceuticals reported a strong Q2 2025 with significant achievements such as the launch of ONAPGO, acquisition of Sage Therapeutics, and robust growth in key products like Qelbree and GOCOVRI. However, challenges remain with declines in legacy product sales, increased operating expenses, and a projected operating loss for 2025. Overall, the positive developments and future growth potential outweigh the negatives.

Company Guidance -

Q4 2025

In the second quarter of 2025, Supernus Pharmaceuticals provided updated guidance, reflecting a strong performance in the first half and the impact of the Sage Therapeutics acquisition. The company raised its full-year 2025 revenue expectations to a range of $670 million to $700 million, up from the previous $600 million to $630 million. This increase is driven by strong sales from products like Qelbree and GOCOVRI, with Qelbree experiencing a 31% growth in net sales and a 23% increase in prescriptions. GOCOVRI prescriptions rose by 14%, with net sales up 16%. The acquisition of Sage Therapeutics, finalized on July 31, introduces ZURZUVAE as a new revenue driver, with its Q2 2025 net revenues reaching $23.2 million, marking a 68% increase from Q1. Supernus also reported that its R&D and SG&A expenses for the full year are expected to rise to $505 million to $530 million due to the Sage acquisition. The company anticipates a full-year operating loss between $70 million to $80 million, influenced by acquisition-related costs. Non-GAAP operating earnings are projected to range from $105 million to $135 million, consistent with previous guidance.

Successful Launch of ONAPGO

Launched ONAPGO in April 2025, the first and only subcutaneous apomorphine infusion device for advanced Parkinson's disease. Over 750 patient enrollment forms submitted by more than 300 prescribers by the end of June 2025.

Acquisition of Sage Therapeutics

Acquired Sage Therapeutics, completed on July 31, 2025. ZURZUVAE, a product from Sage, reported $23.2 million in net revenues in Q2 2025, a 68% increase from the previous quarter.

Strong Performance of Growth Drivers

Qelbree prescriptions grew by 23% and net sales by 31% in Q2 2025. GOCOVRI prescriptions increased by 14% and net sales by 16% in the same period. ONAPGO's launch exceeded expectations.

Impressive Financial Flexibility

Generated strong cash flows, maintaining a cash balance of $523 million as of June 30, 2025, even after funding the Sage acquisition.

Upgraded Revenue Guidance

Increased full-year 2025 revenue guidance to $670 million to $700 million, up from the previous range of $600 million to $630 million.

Supernus Pharmaceuticals (SUPN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SUPN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 03, 2026	2025 (Q4)	- / -	0.746	―	―	―
Aug 05, 2025	2025 (Q2)	0.47 / 0.91	0.771	17.77% (+0.14)	―
May 06, 2025	2025 (Q1)	0.37 / 0.44	0.46	-4.78% (-0.02)	―
Feb 25, 2025	2024 (Q4)	0.52 / 0.75	0.883	-15.52% (-0.14)	―
Nov 04, 2024	2024 (Q3)	0.44 / 1.17	-0.29	502.76% (+1.46)	―
Aug 06, 2024	2024 (Q2)	0.39 / 0.77	-0.02	3955.00% (+0.79)	―
May 08, 2024	2024 (Q1)	0.38 / 0.46	0.29	58.62% (+0.17)	―
Feb 27, 2024	2023 (Q4)	0.55 / 0.88	0.43	105.35% (+0.45)	―
Nov 08, 2023	2023 (Q3)	<0.01 / -0.29	0.03	-1066.67% (-0.32)	―
Aug 08, 2023	2023 (Q2)	0.21 / -0.02	0.546	-103.66% (-0.57)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SUPN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$37.53	$42.44	+13.08%
May 06, 2025	$32.43	$30.94	-4.59%
Feb 25, 2025	$32.81	$31.91	-2.74%
Nov 04, 2024	$34.70	$34.74	+0.12%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Supernus Pharmaceuticals (SUPN) report earnings?

Supernus Pharmaceuticals (SUPN) is schdueled to report earning on Mar 03, 2026, After Close (Confirmed).

What is Supernus Pharmaceuticals (SUPN) earnings time?

Supernus Pharmaceuticals (SUPN) earnings time is at Mar 03, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SUPN EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing